免疫调节剂联合吸入用复方异丙托溴铵溶液治疗慢性阻塞性肺疾病的效果
Effect of Immunomodulators Combined with Compound Ipratropium Bromide Solution for Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease
李晓静 1杨国政2
作者信息
- 1. 山东省青州荣军医院医务科 山东 青州 262500
- 2. 青州市人民医院重症医学科 山东 青州 262500
- 折叠
摘要
目的:探究免疫调节剂联合吸入用复方异丙托溴铵溶液治疗慢性阻塞性肺疾病(COPD)的效果.方法:选择 2017 年 1 月—2019 年 1 月在山东省青州荣军医院呼吸内科治疗的COPD患者 80 例,应用随机数字表法将其分为对照组(吸入用复方异丙托溴铵溶液)及观察组(联合免疫调节剂),各40例,对比两组临床疗效、炎症因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)]、肺功能[最大呼气量(PEF)、最大自主通气量(MVV)、第 1 秒用力呼气容积占预计值的百分比(FEV1%pred)]、气道黏液高分泌[Toll样受体 4(TLR4)、痰液干湿比重、黏蛋白 5AC(MUC5AC)]、不良反应发生率.结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05).治疗前,两组炎症因子比较,差异均无统计学意义(P>0.05);治疗后,两组hs-CRP、TNF-α、PCT均较治疗前降低,且观察组均低于对照组,差异均有统计学意义(P<0.05).治疗前,两组肺功能指标比较,差异均无统计学意义(P>0.05);治疗后,两组PEF、MVV、FEV1%pred均较治疗前升高,且观察组均高于对照组,差异均有统计学意义(P<0.05).治疗前,两组气道黏液高分泌指标比较,差异均无统计学意义(P>0.05);治疗后,两组TLR4 均降低,观察组低于对照组,差异均有统计学意义(P<0.05),痰液干湿比重、MUC5AC均降低,观察组均低于对照组,差异均有统计学意义(P<0.05).观察组不良反应发生率与对照组比较,差异无统计意义(P>0.05).结论:COPD采用免疫调节剂联合吸入用复方异丙托溴铵溶液治疗,效果显著,可改善患者肺功能,抑制炎症反应,缓解气道黏液高分泌状态,安全性较高.
Abstract
Objective:To investigate the effect of immunomodulators combined with Compound Ipratropium Bromide Solution for Inhalation in the treatment of chronic obstructive pulmonary disease(COPD).Method:A total of eighty COPD patients who were treated in the Respiratory Department of Shandong Qingzhou Rongjun Hospital from January 2017 to January 2019 were selected,they were divided into a control group(Compound Ipratropium Bromide Solution for Inhalation)and an observation group(combined with immunomodulators)by random number table method,with 40 cases in each group.The clinical efficacy,inflammatory factors[high-sensitivity C reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),procalcitonin(PCT)],lung function[peak expiratory flow(PEF),maximal voluntary ventilation(MVV),forced expiratory volume at 1 second to predicted value(FEV1%pred)],airway mucus hypersensitivity[Toll like receptor 4(TLR4),sputum wet dry density,mucin 5AC(MUC5AC)]and incidence of adverse reactions of the two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences in inflammatory factors between the two groups(P>0.05);after treatment,hs-CRP,TNF-α and PCT of the two groups were decreased compared to those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in lung function indicators between the two groups(P>0.05);after treatment,PEF,MVV,and FEV1%pred in both groups were increased compared to those before treatment,and those in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in the high secretion of airway mucus between the two groups(P>0.05);after treatment,TLR4 in both groups were decreased,and that in the observation group was lower than that in the control group,the differences were statistically significant(P<0.05),the dry wet ratio of sputum and MUC5AC were decreased,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:The combination of immunomodulators and Compound Ipratropium Bromide Solution for Inhalation is effective in treating COPD.It can improve lung function,inhibit inflammatory reactions,alleviate airway mucus hypersensitivity,and has high safety.
关键词
免疫调节剂/复方异丙托溴铵溶液/雾化治疗/慢性阻塞性肺疾病/肺功能/气道黏液高分泌/炎症因子Key words
Immunomodulators/Compound Ipratropium Bromide Solution/Nebulizer therapy/Chronic obstructive pulmonary disease/Lung function/Airway mucus hypersecretion/Inflammatory factors引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据